Get started
Author

Katerina Chatzidionysiou

Observed names: A Chatzidionysiou, A. Chatzidionysiou, Aikaterina Chatzidionysiou, Aikaterini Chatzidionysiou, Chatzidionysiou, K, Chatzidionysiou, K., Chatzidionysiou, Katerina, K Chatzidionysiou, K. Chatzidionysiou, Katarina Chatzidionysiou, Κ. Chatzidionysiou
Observed institutions: University of Copenhagen, Karolinska University Hospital, University of Helsinki, University of Lisbon, University of Iceland, Eli Lilly (United States), National and Kapodistrian University of Athens, Aarhus University, Aalborg University Hospital, Glostrup Hospital, Aarhus University Hospital, Copenhagen University Hospital, Rigshospitalet, Karolinska Institutet, Institute of Rheumatology, Assistance Publique – Hôpitaux de Paris, University Hospital of Geneva, Laiko General Hospital of Athens, Diakonhjemmet Hospital, Pitié-Salpêtrière Hospital, Institut Pierre Louis d‘Épidémiologie et de Santé Publique, European League Against Rheumatism, Ministry of Social Affairs and Health, Comprehensive Health Research Centre, Université Pierre-et-Marie-Curie, University of Gothenburg, Aalborg University
ORCID: 0000-0002-2669-1247
Observed ORCID: 0000-0002-2669-1247
OpenAlex ID: A5000798254
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
2017 · Josef S Smolen, Robert Landewé, et al. · Annals of the Rheumatic Diseases · 7,371
PDF
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
2021 · The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Pere Domingo, et al. · JAMA · 679
PDF
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis
2017 · Sofia Ramiro, Alexandre Sepriano, et al. · Annals of the Rheumatic Diseases · 358
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
2009 · RF van Vollenhoven, S Ernestam, et al. · The Lancet · 316
Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis
2017 · Katerina Chatzidionysiou, Sharzad Emamikia, et al. · Annals of the Rheumatic Diseases · 278
PDF
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis
2017 · Jackie L Nam, Kaoru Takase-Minegishi, et al. · Annals of the Rheumatic Diseases · 270
PDF
Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature
2016 · Elena Nikiphorou, Helga Radner, et al. · Arthritis Research & Therapy · 270
PDF
Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
2012 · Ronald F van Vollenhoven, Pierre Geborek, et al. · The Lancet · 228
Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries
2011 · Katerina Chatzidionysiou, Elisabeth Lie, et al. · Annals of the Rheumatic Diseases · 223
Delays in assessment of patients with rheumatoid arthritis: variations across Europe
2011 · Karim Raza, Rebecca Stack, et al. · Annals of the Rheumatic Diseases · 154
The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries
2020 · Delphine S Courvoisier, Katarina Chatzidionysiou, et al. · Lara D. Veeken · 95
PDF
Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study
2021 · Hannah Bower, Thomas Frisell, et al. · Annals of the Rheumatic Diseases · 94
PDF
Short- and longer-term cancer risks with biologic and targeted synthetic disease-modifying antirheumatic drugs as used against rheumatoid arthritis in clinical practice
2021 · Viking Huss, Hannah Bower, et al. · Lara D. Veeken · 85
PDF
Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration
2011 · Katerina Chatzidionysiou, Elisabeth Lie, et al. · Annals of the Rheumatic Diseases · 77
Effectiveness of tocilizumab with and without synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a European collaborative study
2015 · Cem Gabay, Myriam Riek, et al. · Annals of the Rheumatic Diseases · 71
PDF
Effectiveness of TNF inhibitor switch in RA: results from the national Swedish register
2014 · Katerina Chatzidionysiou, Johan Askling, et al. · Annals of the Rheumatic Diseases · 68
2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis
2018 · Helga Radner, Katerina Chatzidionysiou, et al. · Annals of the Rheumatic Diseases · 66
PDF
Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma
2024 · Rik J. Verheijden, Femke H. Burgers, et al. · European Journal of Cancer · 65
PDF
Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort
2017 · Noémi Györi, Ioanna Giannakou, et al. · Lupus Science & Medicine · 61
PDF
A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission
2016 · Katerina Chatzidionysiou, Carl Turesson, et al. · RMD Open · 58
PDF
Low rates of remission with methotrexate monotherapy in rheumatoid arthritis: review of randomised controlled trials could point towards a paradigm shift
2019 · Katerina Chatzidionysiou, Petros P Sfikakis · RMD Open · 56
PDF
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration
2016 · Katerina Chatzidionysiou, Elisabeth Lie, et al. · Arthritis Research & Therapy · 49
PDF
Risk of lung cancer in rheumatoid arthritis and in relation to autoantibody positivity and smoking
2022 · Katerina Chatzidionysiou, Daniela di Giuseppe, et al. · RMD Open · 45
PDF
Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort
2013 · K Chatzidionysiou, RF van Vollenhoven · Scandinavian Journal of Rheumatology · 45
Influence ofFCGR3Agenotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study
2012 · Alf Kastbom, Lars Cöster, et al. · BMJ Open · 44
PDF
Works count: 196
Citation count: 12,130
H-index: 31
I10-index: 64
Year
Topic
Type